Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

The hu14.18-IL2 (EMD 273063) IC, consisting of a GD(2)-specific mAb genetically engineered to two molecules of IL-2, is in clinical trials for treatment of GD(2)-expressing tumors. Anti-tumor activity of IC in vivo and in vitro involves NK cells. We studied the kinetics of retention of IC on the sur...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Buhtoiarov, Ilia N., Neal, Zane C., Gan, Jacek, Buhtoiarova, Tatiana N., Patankar, Manish S., Gubbels, Jennifer A. A., Hank, Jacquelyn A., Yamane, Brett, Rakhmilevich, Alexander L., Reisfeld, Ralph A., Gillies, Stephen D., Sondel, Paul M.
Format: Artigo
Idioma:Inglês
Publicat: Society for Leukocyte Biology 2011
Matèries:
Translational & Clinical Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3058817/
https://ncbi.nlm.nih.gov/pubmed/21248148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1189/jlb.0710422
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars